Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy.
Christopher T BuckleyOlivia R WatersGeorge DeMaagdPublished in: The Annals of pharmacotherapy (2020)
As seen in clinical trials, cenobamate as an adjunctive, once-daily treatment represents an efficacious and generally well-tolerated therapy for patients with drug-resistant focal epilepsy.